Crenolanib Approval Status
Crenolanib is benzimidazole type I kinase inhibitor in development for the treatment for multiple cancers, including acute myeloid leukemia (AML) and gastrointestinal stromal tumors (GIST).
Development Status and FDA Approval Process for crenolanib
|Nov 16, 2016||Arog Pharmaceuticals Receives FDA Fast Track Designation for Crenolanib for Advanced Gastrointestinal Stromal Tumors with a D842V Mutation in the PDGFRA Gene|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.